Synergy Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. Co. is engaged in the discovery, research and development activities around analogs of uroguanylin, a naturally occurring and endogenous human GI peptide, for the treatment of GI diseases and disorders. Co. discovered, is developing and controls 100% worldwide rights to its proprietary uroguanylin analog platform. Co.'s commercial product, plecanatide, under trademark name TRULANCE™ is for the treatment of adults with chronic idiopathic constipation and irritable bowel syndrome with constipation. We show 27 historical shares outstanding datapoints in our SGYP shares outstanding history coverage, used to compute SGYP market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing SGYP market cap history over the course of time is important for investors
interested in comparing SGYP's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of SGYP versus a peer is one thing; comparing
SGYP market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like SGYP can fluctuate over the course of history.
With this page we aim to empower investors researching SGYP by allowing them to research the SGYP market cap history. |
Free SGYP Email Alerts:
Video: The Importance of Market Cap
